NewTimeSpace News, according to an announcement disclosed on the Singapore Exchange, Telix announced on April 13 that it has entered into a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies under a 50/50 cost and profit-sharing model.
NewTimeSpace News: Peijia Medical Limited (09996.HK) announced the successful completion of the first patient implant in the US FDA early feasibility study of the GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) System.The procedure was performed by Professor Saibal Kar, Clinical Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles.
GEO enters its operational deployment phase in 2026, as financial institutions pivot their evaluation criteria from binary presence ("have or have not") to scientific efficacy and measurable impact. Youliancloud proposes four golden standards: systematic monitoring, citation-rate penetration through traffic flows, faithful restoration of official investment research logic, and constructing multi-dimensional closed-loop systems for sustainable long-term positioning.
NewTimeSpace: SSY Group Limited (02005.HK) announced that its calcium chloride has been approved by the National Medical Products Administration (NMPA) of China for registration as an active pharmaceutical ingredient (API) for use in marketed finished products.Calcium chloride is mainly indicated for the treatment of calcium deficiency, tetany and other conditions.
NewTimeSpace: MicroPort NeuroScientific Corporation (02172.HK) announced that its independently developed APOLLO Dream® Sirolimus Targeted Eluting Stent System has recently been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).It is the world’s first balloon-expandable, rapid-exchange drug-eluting stent in the neurointerventional field to receive this designation.
NewTimeSpace: Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566.HK) announced that its independently developed JY47 Injection has obtained implicit approval for clinical trials from the National Medical Products Administration (NMPA) of China. The drug is intended for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis.
This guide advocates for a paradigm shift in financial digital asset evaluation via YouLianCloud GEOPlus. It introduces a three-tier framework: the Information Layer focuses on official recall rates for semantic accuracy; the Data Layer emphasizes structural compliance to boost source authority; and the Communication Layer targets multi-source citation frequency to build algorithmic consensus. This L3 standard ensures financial brands achieve high-weight, high-trust visibility in the generative AI search era.
On March 16, SmartMore Inc. officially filed for a Hong Kong IPO. Founded by Dr. Jia Jiaya and backed by the HKIC, the firm reported 2025 revenue of RMB 1.086 billion. Its proprietary IndustryGPT model now serves over 730 global clients, including Tesla and Zeiss. IPO proceeds will primarily fund R&D for industrial multi-modal models and accelerate international commercial expansion.
NewTimeSpace: SSY Group Limited(02005.HK) announced that its Bumetanide has been approved by the National Medical Products Administration (NMPA) of China for registration as an active pharmaceutical ingredient (API) for use in marketed finished products.Bumetanide is a loop diuretic, mainly indicated for the treatment of edema associated with heart failure, renal dysfunction and hepatic dysfunction.
The key to GEO in financial marketing lies in "logical alignment." By leveraging Yoyi Link's GEOPlus across its three-layer architecture of information, data, and dissemination, official viewpoints are transformed into structured assets comprehensible to AI, thereby enhancing retrieval weight.
NewTimeSpace News,On March 12, Singapore-based investment group Trendlines announced that its portfolio company IBI Ag has successfully completed the Proof of Concept (POC) for its AI-powered de novo protein design platform for novel bioinsecticides.
NewTimeSpace: HBM Holdings Limited (02142.HK) announced that the Investigational New Drug (IND) application for HBM7575 (also known as SKB575), a long‑acting bispecific antibody targeting TSLP and an undisclosed target for the treatment of atopic dermatitis, has been approved by the National Medical Products Administration (NMPA) of China.
NewTimeSpace:SSY Group Limited (02005.HK) announced that it has obtained the drug production registration approval from the National Medical Products Administration (NMPA) for Calcium Levofolinate for Injection (25mg). The product is classified as a Class 3 chemical drug and is deemed to have passed the consistency evaluation. It is mainly used for the treatment of gastric cancer and colorectal cancer.
NewTimeSpace: Shanghai Henlius Biotech, Inc. (02696.HK) announced a voluntary announcement that the Phase 1 clinical trial application of HLX97, a self-developed KAT6A/B small-molecule inhibitor, for the treatment of advanced/metastatic solid tumors has been approved by the National Medical Products Administration (NMPA) of China. As of the date of this announcement, no similar products have been approved for marketing worldwide.
Innogen Pharmaceutical-B, which once claimed the title of "Oversubscription King" on the HKEX in 2025, has recently faced a sluggish capital market. As of the close on March 4, 2026, its share price stood at HK$22.28, with a cumulative drop of nearly 20% over the past three days—just a step away from its HK$18.68 offer price. The company’s total market value has shrunk by over HK$10 billion from its early post-listing high to approximately HK$10.18 billion. The company's R&D is highly dependent on a single GLP-1 mechanism. The much-anticipated "weight loss indication" is not expected to complete clinical trials until Q4 2026, with approval potentially pushed to 2027.
As the "first Data Agent stock on the HKEX," Xunce (03317.HK) has demonstrated strong share price performance since its listing at the end of 2025. As of March 3, 2026, the closing price was HK$77.45, up 61.35% from the offer price, and it was included in the Hang Seng Composite Index in just 45 days. However, the enthusiasm in the secondary market cannot hide its fundamental pressures. Core financial and operational warnings: revenue in the first half of 2025 decreased by 30% year-on-year, and the loss for the period expanded to RMB 108 million. R&D expenses remain high, consistently accounting for over 70% of revenue.
